MAX BioPharma reports on the inhibition of profibrotic signaling in cellular models of lung and kidney fibrosis by its oxysterol drug candidate,...
Inhibition of Profibrotic Signaling by Oxy210
read more
News and Events
MAX BioPharma reports on the anti-inflammatory effects of its drug candidate, Oxy210
MAX BioPharma reports on the anti-inflammatory effects of its oxysterol drug candidate, Oxy210, an orally available small moleculedifferent from...
MAX BioPharma receives a Direct-to-Phase II SBIR award from the NIH
MAX BioPharma is pleased to announce that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: “Therapeutic Development...
MAX BioPharma Publishes on its NASH Program and Lead Oxysterol Drug Candidate, Oxy210
MAX BioPharma scientists, along with its UCLA colleagues, publish new paper titled "Oxy210, a novel inhibitor of hedgehog and TGF-β signalling,...
MAX BioPharma Announces Discoveries Regarding Drug Candidates for Targeting COVID-19
In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma scientists have identified...